Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
May 7, 2024 – Clinical Trials, Drug Discovery – ASCO 2024, Gilead Sciences, Kite Pharma, oncology
- Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study
- Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab, to be Presented
- Pilot Study Results of Yescarta (Axicabtagene Ciloleucel) in Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas, an Area of Unmet Clinical Need, to be Presented Orally.
7 May 2024 — Stockley Park, UK — Gilead Sciences and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This data showcases the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumours and blood cancers, including lung, breast, gastrointestinal, colorectal, leukaemia and lymphoma.
New Data Provide Detail on Trodelvy (sacituzumab govitecan-hziy) in Non-Small Cell Lung Cancer (NSCLC)
Gilead is presenting primary results from the global phase 3 EVOKE-01 study of sacituzumab govitecan-hziy versus docetaxel in patients with advanced or metastatic NSCLC that has progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. In addition, Gilead will present longer-term results from Cohort A of the phase 2 EVOKE-02 study of sacituzumab govitecan-hziy in combination with KEYTRUDA (pembrolizumab) in first-line advanced or metastatic squamous/non-squamous PD-L1-high NSCLC.
Gilead Highlights Progress in Gastrointestinal Pipeline
An updated analysis from the phase 2 EDGE-Gastric study will be featured as a rapid oral presentation in partnership with Arcus Biosciences. These longer-term efficacy and safety results for domvanalimab, an Fc-silent anti-TIGIT antibody, plus the anti-PD-1 antibody zimberelimab and chemotherapy, as a potential first-line treatment for upper gastrointestinal cancers, follow the encouraging ORR and six-month PFS rate results from the preliminary analysis presented during the November 2023 virtual ASCO Plenary Series.
Additionally, an oral presentation with our partner Arcus Biosciences will feature data from Cohort B of ARC-9, a phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus zimberelimab, and FOLFOX/bevacizumab in third-line metastatic colorectal cancer (mCRC).
Gilead and Kite Showcase New Data on CAR T-cell Therapies
A pilot collaborative study evaluating Yescarta (axicabtagene ciloleucel) for the treatment of patients with relapsed/refractory (R/R) primary and secondary central nervous system lymphoma (PCNSL and SCNSL) will be presented orally. These updated data will highlight the efficacy and safety of Yescarta in this patient population with important unmet need.
Additionally, updated overall survival and safety outcomes for Tecartus (brexucabtagene autoleucel) from the pivotal phase 1/2 ZUMA-3 trial, now with more than four years of follow up, will be presented. The ZUMA-3 trial has the longest follow-up in an adult-only study of a CAR T-cell therapy for R/R B-cell lymphoblastic leukaemia (B-ALL). These data continue to support the long-term survival and durability of brexucabtagene autoleucel.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California, US. Visit: www.gilead.com.
About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, US, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing. Gilead acquired Kite in 2017. Visit: www.kitepharma.com.
